Orthofix Medical (OFIX) risk factors, FY2025 10-K

Risks Related to our Business and Industry

1. 01We continue to integrate legacy businesses that operate in different market segments, and we may not be able to achieve all of our intended synergies between such legacy businessesNew
2. 02Our business may be adversely affected if consolidation in the healthcare industry leads to demand for price concessions or if a GPO or similar entity excludes us from being a supplier
3. 03Existing and proposed laws, regulations, and industry policies, in both domestic and international markets, regulate or seek to increase regulation of sales and marketing practices and the pricing and profitability of companies in the healthcare industry
4. 04The industry in which we operate is highly competitive. New developments by others could make our products or technologies non-competitive or obsolete44% rewritten
5. 05Our ability to market products successfully depends, in part, upon the acceptance of the products not only by consumers, but also by independent third parties
6. 06Clinical studies are expensive and subject to extensive regulation and their results may not support our product candidate claims or may result in the discovery of adverse effects
7. 07Our allograft and cellular bone allografts could expose us to certain risks that could disrupt our business71% rewritten
8. 08Unfavorable media reports or other negative publicity concerning both alleged improper methods of tissue recovery from donors and disease transmission from donated tissue could limit widespread acceptance of some of our products
9. 09We may not be able to successfully introduce new products to the market and market opportunities that we expect to develop for our products may not be as large as we expect
10. 10develop an effective marketing and distribution network
11. 11result in limitations on the indicated uses of our products
12. 12Growing our business requires that we properly educate and train physicians regarding the distinctive characteristics, benefits, safety, clinical efficacy, and cost-effectiveness of our products
13. 13perceived risk of liability that could be associated with the use of new products, techniques, or technologies
14. 14Sales of, or the price at which we sell, our products may be adversely affected unless the safety and efficacy of our products, alone and relative to competing products, is demonstrated in clinical studies83% rewritten
15. 15We may be adversely affected by any disruption in our information technology systems, which could adversely affect our cash flows, operating results, and financial condition
16. 16We may be adversely affected by a failure or compromise from a cyber-attack, data breach or ransomware attack, which could have an adverse effect on our business
17. 17The physical effects of climate change or legal, regulatory, or market measures intended to address climate change could adversely affect our operations and operating results
18. 18We depend on third-party manufacturers for many of our products
19. 19We depend on a limited number of third-party suppliers for processing activities, components and raw materials and losing any of these suppliers, or their inability to provide us with an adequate supply of materials that meet our quality and other requirements, could harm our business
20. 20If we are unable to maintain and expand our network of independent sales representatives and distributors, we may not maintain or grow our revenue
21. 21In order to compete, we must attract, retain, and motivate executives and key employees, and our failure to do so could have an adverse effect on our results of operations47% rewritten
22. 22Our business is subject to economic, political, regulatory, and other risks associated with international sales and operations
23. 23availability of government subsidies or other incentives that benefit competitors in their local markets that are not available to us; andNew

Risks Related to our Legal and Regulatory Environment

1. 24If we fail to maintain an effective system of internal controls or discover material weaknesses in our internal control over financial reporting, we may not be able to report our financial results accurately or detect fraud, which could harm our business and the trading price of our common stock20% rewritten
2. 25We are subject to the FCPA and other similar anti-bribery laws, and any violations of such laws could subject us to adverse consequences
3. 26We are subject to various healthcare fraud, abuse, and anti-self-referral laws, and could face substantial penalties if we are determined not to have fully complied with such laws
4. 27We continue to be affected by U.S. healthcare reform initiatives
5. 28Implemented payment system reforms including a national pilot program on payment bundling to encourage hospitals, physicians, and other providers to improve the coordination, quality, and efficiency of certain healthcare services through bundled payment models
6. 29We are subject to differing customs and import/export rules in several jurisdictions in which we operate
7. 30The sales and marketing practices of our industry have been the subject of increased scrutiny from federal and state government agencies
8. 31Reimbursement policies of third parties, cost containment measures, and healthcare reform could adversely affect the demand for our products and limit our ability to sell our products
9. 32We and certain of our suppliers may be subject to extensive government regulation that increases our costs and could limit our ability to market or sell our products
10. 33Prohibitions on promotion of "off-label" uses of medical devices might affect the way we market our products and compete in the marketplace
11. 34An FDA panel recommended that bone growth stimulator devices be reclassified by the FDA from Class III to Class II devices, which could increase future competition for us in this product category and negatively affect our future sales of such products
12. 35We are subject to requirements relating to hazardous materials which may impose significant compliance or other costs on us

Risks Related to our Intellectual Property

1. 36We depend on our ability to protect our intellectual property and proprietary rights, but we may not be able to maintain the confidentiality of these assets or assure their protection
2. 37Our success will depend in part on our ability, both in the U.S. and in foreign countries, to operate without infringing upon the patents and proprietary rights of others, and to obtain appropriate licenses to patents or proprietary rights held by third parties if infringement would otherwise occur
3. 38Require us to pay substantial monetary damages or royalties to license proprietary rights from third parties, to satisfy judgments or to settle actual or threatened litigation
4. 39If we seek to protect or enforce our intellectual property rights through litigation or other proceedings, it could require us to spend significant time and money, the results of which are uncertain
5. 40We may be subject to claims that we, our employees, or our independent sales agents or stocking distributors have wrongfully used or disclosed alleged trade secrets of our competitors or are in breach of non-competition or non-solicitation agreements with our competitors

Risks Related to Litigation and Product Liability Matters

1. 41We may be subject to product and other liability claims that may not be covered by insurance and could require us to pay substantial sums
2. 42Ongoing litigation and arbitration matters could negatively affect our business operations44% rewritten

Risks Related to Potential Acquisitions, Investments, and Divestitures

1. 43Our efforts to identify, pursue, and implement new business opportunities (including acquisitions) may be unsuccessful and may have an adverse effect on our business
2. 44We may incur significant costs or retain liabilities associated with disposition activity

Risks Related to Our Financial Results and Financing Needs

1. 45Our quarterly operating results may fluctuate
2. 46We face risks related to foreign currency exchange rates
3. 47Our global operations may expose us to tax risks58% rewritten
4. 48requirement related to such expenditures for activities performed in the U.S. The remaining requirement may have a significant impact on our cash tax liability and our effective tax rate as we perform research and development in the U.S., Italy, and CanadaNew
5. 49A significant portion of our assets consists of goodwill, intangible assets, and fixed assets. The carrying value of these assets may be reduced if we determine that those assets are impaired, including intangible assets from recent acquisitions
6. 50We maintain a $275.0 million credit facility secured by a pledge of substantially all of our property
7. 51The Credit Facilities are secured by a perfected first priority lien, or the equivalent security interest in each applicable jurisdiction, on substantially all of our assets and the applicable guarantors (subject to customary carveouts), including their respective U.S. intellectual property assets49% rewritten
8. 52transactions, as well as financial covenants that we (i) maintain $15.0 million of unrestricted cash in U.S.-based accounts, and (ii) maintain a maximum total debt-to-EBITDA leverage ratio no greater than 4.0x during the term of the facilityNew
9. 53We may need additional financing in the future to meet our capital needs or to make opportunistic acquisitions, and such financing may not be available on favorable terms, if at all
10. 54We must maintain high levels of inventory, which could consume a significant amount of our resources and reduce our cash flows
11. 55We hold our cash and cash equivalents that we use to meet our working capital and operating expense needs in deposit accounts that could be adversely affected if the financial institutions holding such funds fail

General Risks

1. 56Our stock price has fluctuated and may continue to fluctuate, which may make future prices of our stock difficult to predict45% rewritten
2. 57conditions or stock market performance or domestic or international macroeconomic and geopolitical factors unrelated to our performance may also affect the price of our stockNew
3. 58We expend substantial resources to comply with laws and regulations relating to public companies, and any failure to maintain compliance could subject us to regulatory scrutiny and cause investors to lose confidence in our company, which could harm our business and have a material adverse effect on our stock price
4. 59Environmental, social, and corporate governance ("ESG") regulations, policies and provisions may make our supply chain more complex and may adversely affect our relationships with customers21% rewritten
5. 60Our business could be negatively impacted by corporate citizenship and ESG matters and/or our reporting of such matters22% rewritten